Tharimmune, INC 10-Q quarterly reports

Canton Strategic Holdings, Inc. reported its second quarter 2026 financial results, highlighting new revenue from network validation and locking-as-a-service, but also significant unrealized losses on its digital asset holdings.

Canton Strategic Holdings reports a significant increase in net loss for Q1 2026, primarily driven by its digital asset strategy and substantial unrealized losses on its Canton Coin holdings.

Tharimmune, a clinical-stage biotech, reported a reduced net loss in Q3 2025 and secured over $545 million in new capital, including a significant cryptocurrency offering, while also announcing major leadership changes and a new digital asset treasury strategy.

Tharimmune, a clinical-stage biotech, reported continued operating losses and a going concern warning, despite progress in its drug pipeline and recent capital raises, alongside significant management changes.

Tharimmune, a clinical-stage biotechnology company, announced its Q1 2025 financial results, highlighting a net loss of $2.54 million and a strategic shift towards prioritizing its TH104 program for opioid prophylaxis.

Tharimmune Inc. reported a net loss of $3.8 million for the third quarter of 2024, alongside updates on clinical trials and strategic agreements.

Tharimmune, a clinical-stage biotechnology company, released its second quarter 2024 financial results, highlighting progress in clinical trials and strategic pipeline development.

Tharimmune Inc. reported a net loss of $2.26 million for the first quarter of 2024, while advancing its clinical and preclinical programs.